{Reference Type}: Journal Article
{Title}: [Consensus recommendations on utilizing glucagon-like peptide-1(GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus].
{Author}:  ; ;
{Journal}: Zhonghua Nei Ke Za Zhi
{Volume}: 59
{Issue}: 11
{Year}: Nov 2020 1
暂无{DOI}: 10.3760/cma.j.cn112138-20200704-00646
{Abstract}: Glucagon-like peptide-1 receptor agonists (GLP-1RA) not only significantly lower blood glucose but also reduce multiple cardiovascular risk factors. Moreover, some of this class of anti-diabetic drugs have been shown to have beneficial effects in cardiovascular outcome trials. This expert consensus is developed for the optimal use of GLP-1RA in individualized treatment of type 2 diabetes mellitus (T2DM) and includes the timing of GLP-1RA use in the glucose-lowering therapeutic algorithm, the precautions while combined with other anti-diabetic drugs, the therapeutic benefits while preferably added on the anti-diabetic therapies for patients with T2DM and atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD), and the use of GLP-1RA in special population of patients with T2DM.<BR>胰高糖素样肽-1受体激动剂（GLP-1RA）不仅显著降低2型糖尿病（T2DM）患者的血糖，还可以改善多种心血管危险因素，部分GLP-1RA被证实具有明确的心血管保护作用。本共识针对GLP-1RA降糖治疗的应用时机，与其他降糖药物联用时的注意事项，对T2DM合并动脉粥样硬化性心血管疾病（ASCVD）、心力衰竭（HF）或慢性肾脏疾病（CKD）患者治疗结局的影响，在T2DM特殊人群中的应用等临床问题给出了具体的推荐意见。.